AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2024 Earnings Call Transcript February 27, 2025
AbCellera Biologics Inc. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.15.
Operator: Good afternoon and welcome to AbCellera’s Full Year 2024 Business Update Conference Call. My name is Tamia [ph] and I will facilitate the audio portion of today’s interactive broadcast. [Operator Instructions] At this time, I would like to turn the call over to Tryn Stimart, AbCellera’s...
